US ENDOCRINOLOGY
Most clinical providers are reluctant to modify ART regimens with the purpose of controlling hyperlipidemia due to the potential risk for virologic failure or drug intolerance. Consequently, the use of lipid-modifying therapies that can be used in combination with ART is preferred. While statin therapy has been associated with reduced mortality in HIV-infected patients in one clinical cohort, 22 no randomized clinical trials have been conducted to confirm these findings. Thus some have raised concerns regarding toxicity secondary to drug interactions between statins and ART. This article will discuss the challenges of statin therapy in HIVinfected patients on ART with hyperlipidemia.
Hyperlipidemia in HIV-infected Individuals
HIV infection has been associated with abnormalities in lipid profiles even in the absence of ART, increasing the risk for CVD. 1, 23 The natural history of HIV infection is associated with a characteristic evolving pattern of lipid parameters. There is an initial decrease in high-density lipoprotein cholesterol (HDL-C) followed by a decrease in low-density lipoprotein cholesterol (LDL-C). In more advanced disease, there is an increase in triglycerides (TG) and in very LDL cholesterol (VLDL-C). 24 Initiation of ART causes lipid levels to return to baseline levels and subsequently increase above pre-seroconversion levels, except for HDL-C, which remains persistently low (see Table 1 ). 15, 25 Decreased HDL-C levels resulting from altered HDL metabolism is a typical feature of HIV-infection even after ART is initiated. 26, 27 The magnitude of these changes varies widely among patients depending on individual characteristics such as ethnicity/race, or mitochondrial haplotypes.
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Antiretroviral Therapy and Hyperlipidemia
Conventional ART consists of a combination of three medications drawn from multiple drug classes: nucleoside reverse transcriptase (RT)
inhibitors (NRTIs-nucleoside [or nucleotide] analogs, which inhibit the viral RT enzyme); non-NRTI inhibitors (NNRTIs), which also inhibit the RT enzyme; PIs, which act on the HIV protease; integrase inhibitors, which block the action of the viral enzyme integrase; and CCR5 inhibitors, which block the CCR5 co-receptor on CD4+ T-cells. The use of ART produces negative changes on lipid parameters including total cholesterol (TC), LDL-C, and TG. 17 HIV itself also contributes to these detrimental effects on lipids, most notably via a persistent decrease in HDL-C. The typical lipid pattern is one of low HDL-C levels, excess TC, and increased levels of small LDL particles (see Figure 1) . 18, 29 This creates deleterious alterations in the lipid profiles of HIV patients that require attention and management.
In HIV-infected individuals treated with ART agents, differences in serum lipids have been observed between and within drug classes. 30 PIs generally increase levels of LDL-C and TG (see Table 2 ). 30 Ritonavir inhibits the cytochrome P450 3A4 isoenzyme and is co-administered with PIs to boost their plasma concentrations, resulting in improved efficacy and reduced pill burden. 31 Ritonavir-boosted PIs generally result in similar lipid profiles in HIV-infected patient cohorts. However, tipranavir, which must be boosted with a higher ritonavir dose than other PIs, is associated with substantial elevations in TC and TG. 32 A review of clinical trials of first-line ARTs with available lipids data found that fosamprenavir/ritonavir and lopinavir/ ritonavir in combination with NRTIs other than tenofovir caused the highest lipid elevations at 48 weeks. 33 Atazanavir and darunavir cause modest increases in lipids compared with other PIs. [34] [35] [36] A recent study comparing ritonavir with cobicistat, when used as a booster of atazanavir, plus an NRTI, showed no significant differences in lipid levels at 48 weeks. 37 Non-NRTI inhibitors increase lipids only modestly (see Table 3 ). The addition of the NNRTI efavirenz to a NRTI backbone results in small increases in all lipids including HDL-C. 38 A head-to-head comparison of nevirapine and efavirenz demonstrated that nevirapine had the most favorable effects on lipid profile. 39 The addition of etravirine to a PI+NRTI regimen does not result in additional lipid elevations. 40 Rilpivirine appears to have even more modest effects on lipids compared with efavirenz. 41, 42 33 Some studies suggest that tenofovir may have independent lipid-lowering properties. 43, 44 Other ART agents such as integrase inhibitors (e.g., raltegravir, dolutegravir, and elvitegravir) and the fusion inhibitors enfuvirtide have not been associated with significant lipid changes. [45] [46] [47] [48] The CCR5 inhibitor maraviroc does not increase lipids and may be associated with lipid reductions in dyslipidemic patients. 49 A study comparing the co-formulations elvitegravir/ cobicistat/tenofovir/emtricitabine with efavirenz/tenofovir/emtricitibine found lower lipid increases in the elvitegravir fixed-dose combination arm at 48 weeks.
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Management of Hyperlipidemia in HIV-infected Individuals Clinical Guidelines
The and calculates both the 10-year and lifetime risk for CVD. In young patients, the 10-year risk can be low, but the lifetime risk can be high. This can be of importance in deciding which HIV-infected patients should be treated with statins. 52 The ACC/AHA guidelines recommend statin therapy for individuals at increased CVD risk who are most likely to experience a net benefit in terms of the potential to reduce CVD events and the potential for adverse effects. They also suggest the use of statins to prevent both non-fatal and fatal CVD events. 52 The implications of these new guidelines for those with HIV infection are unclear at this time.
Both the NCEP ATP III and the ACC/AHA guidelines recommend initiation of statin therapy for elevated non-HDL-C when TG levels are between 200
and 500 mg/dL. If the TG level is higher than 500 mg/dL, initial treatment with a fibrate is recommended. 53 The International Atherosclerosis Society has also recently published their recommendations of dyslipidemia.
These emphasize the importance of non-HDL cholesterol (non-HDL-C) as the major atherogenic lipoprotein and estimate lifetime risks for CVD. 54 To date, guidelines that recommend lipid-lowering therapies for use in 
Antiretroviral Therapy Interruption
Interruption of ART has been considered as an option for correcting lipid abnormality; however, this strategy was discredited as unreasonable after a clinical study among HIV-infected subjects found an increased risk for cardiovascular events observed in patients undergoing intermittent
ART compared with those on continuous ART. 57 It is believed that the deleterious effect of circulating HIV greatly outweighs the potential benefit of reduced LDL-C and TC in untreated HIV infection.
Antiretroviral Therapy Modification
A strategy of switching the ART regimen to one with fewer negative effects on lipid metabolism has demonstrated benefits on lipid parameters. 49, 50, [58] [59] [60] [61] In some cases, however, this strategy may not result in the desired lipid level targets. Patients with pre-existing dyslipidemia prior to initiation of ART that worsens while on ART are unlikely to achieve a normalization of lipids without the use of lipid-lowering drugs. 53 In addition, switching ART carries a risk for virologic failure, particularly in patients with an underlying drug-resistant virus. 62 Management of dyslipidemia through ART modification should be reserved only for patients with significant lipid abnormalities on the current ART regimen who cannot achieve lipid control with available lipid-lowering pharmacotherapy or do not tolerate lipid-lowering drugs.
Use of Lipid-lowering Therapy [63] [64] [65] Statins are rapidly absorbed, reaching a peak concentration within 4 hours and most exhibit low bioavailability (5-14 % for simvastatin, lovastatin, atorvastatin, 20-30 % for fluvastatin, pravastatin, rosuvastatin, and 60 % for pitavastatin). 66 Elimination half-lives of the statins range from less than 5 hours for fluvastatin, lovastatin, pravastatin, and simvastatin to 11 hours for pitavastatin and 20 to 30 hours for atorvastatin and rosuvastatin.
Lovastatin, simvastatin, and atorvastatin are extensively metabolized by the cytochrome P450 (CYP) isoenzyme CYP3A4, while rosuvastatin, pitavastatin, and pravastatin undergo minimal metabolism via CYP isoenzymes and are eliminated primarily unchanged in bile and urine. 66 The selection of lipid-lowering medications that are potent, effective, and safe to administer while taking into account interactions with ART agents and other drugs, such as antifungals, presents an important challenge for clinical providers treating HIV-infected patients. Data on the safety of statin use comes primarily from non-HIV-infected populations. In addition, the safety of statins has not been conclusively evaluated in patients co-infected with HIV and hepatitis C viruses, where potential statin hepatotoxicity is a safety concern. A small study suggested that statin use was safe in this patient population but recommended further evaluation with a prospective controlled trial to definitively answer this safety concern.
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Many ARTs inhibit or induce major metabolic pathways of statins, creating potentially serious DDIs (see Table 4 ). Failure to recognize these DDIs can result in toxicity due to excessive plasma statin concentrations, leading to myopathy or rhabdomyolysis, or in the inability to reach lipid control targets due to sub-therapeutic statin levels in blood.
Drug-Drug Interactions of Protease inhibitors Co-administered with Statins
PIs inhibit CYP3A4: ritonavir is the most potent CYP3A4 inhibitor, which has led to its use as a pharmacologic booster for other PIs. Cobicistat, another pharmacokinetic booster that is devoid of anti-HIV activity, is believed to be more selective than ritonavir as it does not induce non-CYP3A4 drugmetabolizing pathways. 68 Several statins also depend on CYP3A4 for metabolic clearance. The co-administration of PIs is therefore a cause for concern in terms of side effects and DDIs, and can result in elevated plasma levels of statins. 69 In 2012, the FDA released a safety announcement, recommending dose restrictions on rosuvastatin and atorvastatin when combining statins with PIs. 9 
Simvastatin and Lovastatin
The most serious DDI between statins and PIs involve simvastatin and lovastatin. The simvastatin area under the curve (AUC) increases sixfold when co-administered with the unboosted PI nelfinavir and 30-fold when coadministered with ritonavir-boosted saquinavir. 69 Cases of rhabdomyolysis have been described with the concomitant use of simvastatin and boosted indinavir 69 and also with unboosted atazanavir when another CYP3A4 inhibitor (amiodarone) was inadvertently administered. 70 As a result of these data, lovastatin, which has similar pharmacokinetic properties to simvastatin, is contraindicated for patients taking PIs. 9 This contraindication can be extended to patients taking other CYP3A inhibitors, including any ARV combined with cobicistat, such as the fixed-dose combination elvitegravir/cobicistat/tenofovir/emtricitabine.
Atorvastatin
The co-administration of atorvastatin and PIs results in increases in its AUC.
A fourfold increase in atorvastatin AUC has been reported with ritonavir-boosted saquinavir. 66 Tipranavir co-administration results in a 4.4-fold increase in the AUC of atorvastatin. 71 Fosamprenavir induces an increase of atorvastatin AUC of 130-153 %. 72 Co-administration of atorvastatin 10 mg with twice-daily darunavir 300 mg boosted with ritonavir 100 mg resulted in a 3.4-fold increase in the atorvastatin AUC. 73 Therefore, the FDA has recommended avoiding the use of atorvastatin with tipranavir, using atorvastatin with caution at the lowest possible dose with lopinavir/ ritonavir, and not exceeding an atorvastatin dose of 20 mg when combined with saquinavir, fosamprenavir, or darunavir. 9 
Rosuvastatin
Rosuvastatin is not a substrate, inhibitor, or inducer of CYP3A4. However, it is a substrate of organic anion-transporting polypeptide 1B1 (OATP1B1) and breast cancer-resistance protein (BCRP). PI-induced inhibition of OATP1B1
can cause a decrease in hepatocyte uptake of rosuvastatin while inhibition of BCRP decreases hepatobiliary excretion and increases rosuvastatin absorption, leading to possible DDIs when rosuvastatin is co-administered with PIs. 71 When co-administered with lopinavir, the rosuvastatin AUC increases only slightly but the maximum concentration of drug in serum (maximum drug concentration [C max ]) increases 3.6-fold. 74 When coadministered with atazanavir, increases in the AUC and C max of rosuvastatin of 213 % and 600 %, respectively, have been reported. Co-administration of rosuvastatin with ritonavir-boosted darunavir increases the rosuvastatin AUC by 48 %. 74 The concomitant use of rosuvastatin and tipranavir leads to a modest increase in rosuvastatin AUC of 37 % but a significant increase in rosuvasatin C max of 223 %. 71 Therefore, this combination should be avoided or used cautiously starting with the lowest dose possible of rosuvastatin of 5 mg daily. 71 The FDA recommends a maximum rosuvastatin dose of 10 mg daily when co-administered with boosted atazanavir or lopinavir. 9 
Fluvastatin
There is a lack of data on DDIs between ART drugs and fluvastatin. Since this statin is metabolized primarily via CYP2C9, DDIs are unlikely with most PIs. Ritonavir is a known CYP2C9 inducer and could, theoretically, cause a reduction in the fluvastatin AUC when co-administered. 66 Due to this lack of empirical data, it would seem more prudent to use other statins with better-studied pharmacokinetics when co-administered with ART agents.
Pravastatin
Pravastatin is metabolized mostly by glucuronidation and only minimally by CYP3A4, 69 and can therefore be used safely with most PIs. 51 However, when co-administered with nelfinavir 75 or saquinavir 66 the pravastatin AUC is reduced by about 50 %, thus limiting its potential lipid lowering effectiveness. On the other hand, pravastatin AUC is practically unaffected by co-administration with lopinavir/ritonavir and is increased nonsignificantly by 81 % in the presence of boosted darunavir. Of note, subjects with low functioning haplotype forms of the SLCO1B1 drug transporter gene had significantly increased pravastatin AUC compared with those with wild-type forms-an effect that was maintained in the presence of boosted darunavir. 76 It is recommended that the lowest-possible dose of pravastatin, atorvastatin, or rosuvastatin be used in patients taking darunavir. 73 
Pitavastatin
Like pravastatin, pitavastatin is metabolized mostly by glucuronidation and minimally by CYP. 77 As a result, pitavastatin does not interact with CYP34A
inhibitors and therefore undergoes few DDIs compared with other statins. 78, 79 In healthy volunteers, pitavastatin in combination with lopinavir/ritonavir, darunavir/ritonavir, and atazanavir has shown modest DDIs, requiring no Since pravastatin is substrate of the organic anion transporters OTAP-C and MRP-2, efavirenz may be an inducer of these transporters, resulting in increased hepatic elimination of pravastatin. 83 Therefore, higher doses of these statins may be required for use with efavirenz. No dose adjustment is required for pitavastatin when co-administered with efavirenz.
Pharmacokinetic data showed no significant changes in pitavastatin AUC and C max in the presence of efavirenz.
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Data on statin DDIs with second-generation NNRTIs (etravirine and rilpivirine) are limited. Etravirine is metabolized via several CYP enzymes including CYP3A4, CYPC2C9, and CYP2C19. It is an inducer of CYP3A and inhibits CYP2C9 and CYP2C19. When etravirine was co-administered with atorvastatin 40 mg, the atorvastatin AUC was unchanged but the C max was reduced by 37 %. 84 Since lovastatin and simvastatin are CYP3A4 substrates, co-administration with etravirine may result in lower concentrations of these statins and may require higher doses. Fluvastatin and pitavastatin are metabolized at least in part by CYP2C9 and co-administration with etravirine may result in increased AUC of these statins although actual pharmacokinetic data are lacking. 84 No dose adjustments are required when rilpivirine is co-administered with simvastatin, lovastatin, atorvastatin, rosuvastatin, pravastatin, or pitavastatin. 85 
Drug-Drug Interactions between Other Antiretrovirals and Statins
The integrase inhibitor raltegravir is metabolized through uridine diphosphate-glucuronosyltransferase 1A1 (UGT1A1) glucuronidation and does not inhibit or induce CYP450 isoenzymes such as CYP3A4. 86 Therefore, it is not expected to interact significantly with statins. A study has confirmed the lack of significant interaction between pravastatin and raltegravir. 87 Another integrase inhibitor, elvitegravir, is co-formulated with cobicistat, which is an inhibitor of CYP3A and CYP2D6, and also inhibits numerous transporter proteins including (P-gp), BCRP, OATP1B1, and OATP1B3.
Thus, co-administration of this fixed-dose combination with statins that are primarily metabolized by CYP3A, or are substrates of P-gp, BCRP, OATP1B1, or OATP1B3, may result in increased plasma concentrations of such drugs. Elvitegravir is a modest inducer of CYP2C9 and may decrease the plasma concentrations of CYP2C9 substrates, such as pravastatin.
Co-administration of the four drug fixed-dose combinations (containing elvitegravir, cobicistat, tenofovir, and emtricitabine) with rosuvastatin 10 mg resulted in an increase of the rosuvastatin AUC and C max by 89 % and 38 %, respectively. 88 The manufacturer's prescribing information recommends that atorvastatin should be initiated at the lowest starting dose and titrated carefully while monitoring for safety. Simvastatin and lovastatin are contraindicated when using this fixed-dose combination. HIV-infected patients showed that NCEP targets were achieved at week 12
for LDL-C, HDL-C, and TG in 9 %, 66 %, and 48 % of patients on fenofibrate compared with 36 %, 49 %, and 18 % of those on pravastatin, respectively.
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Markers of inflammation and platelet activation including plasminogenactivator inhibitor type 1 (PAI-1), P-selectin, and high-sensitivity C-reactive protein (hs-CRP) did not change significantly. 94 Data from a retrospective cohort at two large HIV clinics found that the most commonly prescribed statins were atorvastatin and pravastatin, followed by rosuvastatin. One year after starting statin therapy, patients taking atorvastatin or rosuvastatin had significantly greater decreases in TC, LDL-C, and non-HDL-C than patients on pravastatin. 
Diabetes and Statin Use
Several recent general population studies, including two meta-analyses 99, 100 and an analysis from the Women's Health Initiative study, 101 showed an association between statin use and new-onset diabetes. However, the absolute risk appears to be low and is likely offset by the benefit in reduction of CHD resulting from statin use. 99, 102 This finding is of concern as HIV infection and ART are associated with increased insulin resistance and diabetes, 103 but confirmatory studies are needed in the HIV-infected population. However, the benefits of lipid control with the use of statins are still likely to outweigh the possible increase in risk for diabetes onset.
Addressing other risk factors for diabetes, such as obesity through lifestyle modification and regular glucose monitoring, is warranted.
Additional Benefits of Statins in HIV
Statins are known to have pleiotropic beneficial effects that are independent of their lipid-lowering properties. Their anti-inflammatory and non-lipidassociated cardioprotective properties have been demonstrated in non-HIV infected populations. Statin therapy is associated with reductions in CRP in the general population. 104, 105 However, most studies exploring statins in the HIV-infected population have failed to note such a decrease, which may be due to the lack of sensitivity and specificity of the assay in those with underlying inflammation and immune activation. 53 In vitro studies suggest that statin use is also associated with improvements in vascular senescence markers in HIV-infected patients taking PIs. 106 The identification of appropriate markers of inflammation to be used as surrogate Statin use has also been recently associated with reduced cancer incidence and mortality in both the general population and among HIVinfected subjects, 108-110 although reduced cancer incidence has not been reported in all statin studies. 111 A clinical endpoint trial in HIV-infected patients without dyslipidemia may be required to assess the effect of statins on morbidity and mortality in this population.
Conclusion
As HIV has evolved to become a chronic disease, the HIV population is 
